--- title: "Supernus Pharmaceuticals (SUPN) news: class action and merger" url: "https://aibio.space/companies/supernus-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "SUPN class action and merger news: Supernus inherits Sage securities class action, derivative suits and SEC subpoena. Supernus Pharmaceuticals, Inc." --- SUPN Supernus Pharmaceuticals, Inc. NASDAQ · United States # Supernus Pharmaceuticals (SUPN) news SUPN class action and merger news Distress · 2026-10-26 ## [Supernus ends its UBS credit line ahead of the Indivior merger](https://aibio.space/news/supernus-ends-ubs-credit-line-ahead-indivior-merger/) Supernus ended its UBS credit line on October 20, 2026, with nothing drawn and no penalty. The filing says the combined company is to enter a new senior secured facility at closing, but it gives no closing date and no terms. ## Latest Supernus Pharmaceuticals news 1. 2026-10-15 Legal [Supernus inherits Sage securities class action, derivative suits and SEC subpoena](https://aibio.space/news/supernus-inherits-sage-securities-class-action-derivative-suits-sec/) Supernus (Nasdaq: SUPN) took on Sage's New York class action naming Barry Greene and Kimi Iguchi, three derivative suits against sixteen unnamed insiders, and an SEC subpoena. Supernus faces two merger suits of its own. 2. 2026-08-03 Debt Financing [Supernus and Indivior plan merger backed by $650 million Citibank loan](https://aibio.space/news/supernus-indivior-plan-merger-backed-650-million-citibank-loan/) Supernus and Indivior agreed to an all-stock merger that includes a $1.0 billion cash dividend to Indivior stockholders. The companies say a $650 million Citibank term loan commitment will help fund it, and they expect the deal to close in the fourth quarter of 2026. 3. 2026-08-03 Legal [Supernus faces January 2027 APOKYN antitrust trial; related insurance suits pending](https://aibio.space/news/supernus-faces-january-2027-apokyn-antitrust-trial-related-insurance/) Sage Chemical and TruPharma sued Supernus, Britannia, US WorldMeds and others in Delaware. Four individuals were dismissed in 2024. Insurance coverage suits tied to an unnamed Delaware action are open. 4. 2026-04-07 Mergers [Supernus acquires Navitor's NV-5138 assets for a study pledge and up to $350 million in milestones](https://aibio.space/news/supernus-acquires-navitors-nv-5138-assets-study-pledge-up-350-million/) Supernus agreed on April 1, 2026 to buy the NV-5138 assets from Navitor. The price is an obligation to complete one Phase 2b study plus milestone payments of up to $350 million, and Supernus may stop pursuing the milestones if it judges the study unsuccessful. 5. 2025-07-31 Mergers [Supernus completes Sage Therapeutics acquisition after tender offer, $8.50 per share plus CVR](https://aibio.space/news/supernus-completes-sage-therapeutics-acquisition-after-tender-offer-8/) Supernus completed its acquisition of Sage Therapeutics on July 31, 2025 after a tender offer, paying $8.50 in cash per share plus a contingent value right worth up to $3.50. The filing puts the cash consideration at about $561 million, and says no CVR payment is assured. ## Supernus Pharmaceuticals at a glance - **Ticker**: SUPN - **Listing**: NASDAQ - **Country**: United States - **Cash, Sep 30, 2026**: $175.9 million ### Related companies - [TETRALOGIC PHARMACEUTICALS CORP](https://aibio.space/companies/tetralogic-pharmaceuticals/) OTC: TLOG - [Matinas Biopharma Holdings](https://aibio.space/companies/matinas-biopharma/) AMEX: MTNB - [Legend Biotech](https://aibio.space/companies/legend-biotech/) NASDAQ: LEGN - [Aoxing Pharmaceutical Company](https://aibio.space/companies/aoxing-pharmaceutical/) OTC: AOXG - [Clene](https://aibio.space/companies/clene/) NASDAQ: CLNN - [Rezolute](https://aibio.space/companies/rezolute/) NASDAQ: RZLT - [Bicara Therapeutics](https://aibio.space/companies/bicara-therapeutics/) NASDAQ: BCAX - [Achieve Life Sciences](https://aibio.space/companies/achieve-life-sciences/) NASDAQ: ACHV ### Also on NASDAQ - [Polyrizon](https://aibio.space/companies/polyrizon/) PLRZ - [Ionis Pharmaceuticals](https://aibio.space/companies/ionis-pharmaceuticals/) IONS - [Schrodinger](https://aibio.space/companies/schrodinger/) SDGR - [Hyperfine](https://aibio.space/companies/hyperfine/) HYPR - [GH Research](https://aibio.space/companies/gh-research/) GHRS - [Kyverna Therapeutics](https://aibio.space/companies/kyverna-therapeutics/) KYTX ## What Supernus Pharmaceuticals does Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for central nervous system diseases. Its approved treatments address attention-deficit hyperactivity disorder, dyskinesia and OFF episodes in Parkinson's disease, postpartum depression, epilepsy, migraine, cervical dystonia and chronic sialorrhea. Qelbree is a non-stimulant treatment for ADHD in adults and pediatric patients. GOCOVRI is indicated for dyskinesia in Parkinson's patients receiving levodopa-based therapy. ZURZUVAE is the first and only FDA approved oral medicine indicated for postpartum depression in adults and became commercially available in the U.S. in December 2023. Biogen is the collaboration partner jointly commercializing ZURZUVAE. The company completed its acquisition of Sage Therapeutics, Inc. on July 31, 2025, at $8.50 per share in cash plus one contingent value right per share, worth up to $3.50 per share. The company also markets Trokendi XR, Oxtellar XR and APOKYN and has several product candidates in development. | Product or program | What it is | Stage | |---|---|---| | Qelbree | Viloxazine extended-release non-stimulant for ADHD | approved | | GOCOVRI | Amantadine extended-release capsules for dyskinesia in Parkinson's disease | approved | | APOKYN | Apomorphine injection for OFF episodes in advanced Parkinson's disease | approved | | Trokendi XR | Once-daily extended-release topiramate for epilepsy and migraine prevention | approved | | Oxtellar XR | Once-daily extended-release oxcarbazepine for partial-onset seizures | approved | | ZURZUVAE | Oral neuroactive steroid for postpartum depression in adults | approved; commercially available in the U.S. | Summarised from the company's [10-K filed Mar 2, 2026](https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/supn-20251231.htm). ## Supernus Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$106.2 million](https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/) | [$108.8 million](https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/) | | Net income (loss) | [-$38.5 million](https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/) | [$73.9 million](https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/) | | Cash from operations | [$47.3 million](https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/) | [$172.0 million](https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/) | | Cash and equivalents | [$128.4 million](https://www.sec.gov/Archives/edgar/data/1356576/000135657626000051/) | [$69.3 million](https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/) | Latest balance sheet, Sep 30, 2026 (10-Q): cash and equivalents $175.9 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Supernus Pharmaceuticals Is there a class action against Supernus Pharmaceuticals? Our latest story on this, dated Oct 15, 2026: "Supernus inherits Sage securities class action, derivative suits and SEC subpoena". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/supernus-inherits-sage-securities-class-action-derivative-suits-sec/). Is Supernus Pharmaceuticals involved in a merger or acquisition? Our latest story on this, dated Oct 26, 2026: "Supernus ends its UBS credit line ahead of the Indivior merger". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/supernus-ends-ubs-credit-line-ahead-indivior-merger/). What is the ticker symbol of Supernus Pharmaceuticals? Supernus Pharmaceuticals, Inc. trades under the ticker SUPN on NASDAQ. Where is Supernus Pharmaceuticals listed? Supernus Pharmaceuticals, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:S49; LSE:0LB2; LSX:A1JX3U. What is the SEC CIK of Supernus Pharmaceuticals? The SEC Central Index Key (CIK) for Supernus Pharmaceuticals, Inc. is 1356576. Its filings are on SEC EDGAR. How many shares does Supernus Pharmaceuticals have outstanding? 58,127,013 shares as of 2026-07-28, per the cover page of its 10-Q filed 2026-08-03. Which country or territory is Supernus Pharmaceuticals listed under? Our directory records Supernus Pharmaceuticals, Inc. under United States. What does Supernus Pharmaceuticals do? Our directory classifies Supernus Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Supernus Pharmaceuticals? The ISIN recorded for Supernus Pharmaceuticals, Inc. is US8684591089. Does aibio.space cover Supernus Pharmaceuticals? aibio.space lists Supernus Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Supernus Pharmaceuticals incorporated? SEC records list its state or country of incorporation as DE. What does Supernus Pharmaceuticals develop? Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for central nervous system diseases. Its approved treatments address attention-deficit hyperactivity disorder, dyskinesia and OFF episodes in Parkinson's disease, postpartum depression, epilepsy, migraine, cervical dystonia and chronic sialorrhea. What is Qelbree from Supernus Pharmaceuticals? Qelbree: Viloxazine extended-release non-stimulant for ADHD Stage: approved. What is GOCOVRI from Supernus Pharmaceuticals? GOCOVRI: Amantadine extended-release capsules for dyskinesia in Parkinson's disease Stage: approved. Is Supernus Pharmaceuticals profitable? Supernus Pharmaceuticals, Inc. reported a net loss of $38.5 million for the fiscal year ended Dec 31, 2025, and generated $47.3 million of cash from operations, per its annual report to the SEC. ## Investor discussion: Supernus Pharmaceuticals Members talk about Supernus Pharmaceuticals (SUPN). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Supernus Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-10-26 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1356576/000135657626000045/supn-20261026.htm) 2. 2026-10-06 Mergers Filed documents for a merger or acquisition. SEC Form 425. [Source](https://www.sec.gov/Archives/edgar/data/1356576/000110465926113884/tm2627021d2_425.htm) 3. 2026-08-03 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1356576/000110465926089425/tm2622009d1_ex99-1.htm) 4. 2026-04-07 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1356576/000110465926040497/tm2611273d1_8k.htm) 5. 2025-08-05 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1356576/000135657625000055/supn-20250630.htm) 6. 2025-06-16 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1356576/000110465925059687/tm2518064d1_ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:SUPN on TradingView](https://www.tradingview.com/symbols/NASDAQ-SUPN/). ## SEC filings and registration - **SEC name**: Supernus Pharmaceuticals, Inc. - **CIK**: 1356576 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: SUPN (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 9715 KEY WEST AVENUE, ROCKVILLE, MD, 20850 - **Phone**: 301-838-2500 - **Shares outstanding**: 58,127,013 as of 2026-07-28 (10-Q filed 2026-08-03) - **Former names**: SUPERNUS PHARMACEUTICALS INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1356576/000110465926117937/tm2628092d1_8k.htm) filed 2026-10-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1356576/000135657626000043/supn-20261019.htm) filed 2026-10-19 - [8-K](https://www.sec.gov/Archives/edgar/data/1356576/000135657626000040/supn-20261015.htm) filed 2026-10-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1356576/000110465926089839/tm2622009d7_8k.htm) filed 2026-08-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1356576/000110465926089524/tm2622009d4_8k.htm) filed 2026-08-03 - [10-Q](https://www.sec.gov/Archives/edgar/data/1356576/000135657626000037/supn-20260630.htm) filed 2026-08-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1356576/000135657626000035/supn-20260803.htm) filed 2026-08-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1356576/000110465926089425/tm2622009d1_8k.htm) filed 2026-08-03 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001356576), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Supernus Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SUPN, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Supernus Pharmaceuticals, Inc. - **Ticker**: SUPN - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US8684591089 - **Other listed symbols**: GETTEX:S49; LSE:0LB2; LSX:A1JX3U - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-SUPN/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/supernus-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Supernus Pharmaceuticals (SUPN) news: class action and merger", 2026-10-31, https://aibio.space/companies/supernus-pharmaceuticals/